問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberD9670C00001
NCT Number(ClinicalTrials.gov Identfier)-
Active

2020-07-01 - 2027-12-31

Phase III

Recruiting8

ICD-10C50.911

Malignant neoplasm of unspecified site of right female breast

ICD-10C50.912

Malignant neoplasm of unspecified site of left female breast

ICD-10C50.919

Malignant neoplasm of unspecified site of unspecified female breast

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9174.9

Malignant neoplasm of female breast, unspecified

-

  • Trial Applicant

  • Sponsor

    -

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/05/14

Investigators and Locations

Principal Investigator

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Ling-Ming Tseng Division of General Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Wei-Pang Chung Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator HWEI-CHUNG WANG Division of General Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 陳威宇 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 張源清 Division of General Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Shin-Cheh Chen Division of General Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Chiun-Sheng Huang

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Study Contacts

- -

Condition/Disease

-

Objectives

-

Test Drug

-

Active Ingredient

-

Dosage Form

Dosage

-

Endpoints

-

Inclution Criteria

-

Exclusion Criteria

-

The Estimated Number of Participants

  • Taiwan

    30 participants

  • Global

    850 participants